DUBLIN--(BUSINESS WIRE)--The "Irritable Bowel Syndrome - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This Irritable bowel syndrome - Pipeline Insight, 2021 report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Irritable bowel syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Irritable bowel syndrome Emerging Drugs Chapters
This segment of the Irritable bowel syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Irritable bowel syndrome Emerging Drugs
Olorinab: Arena Pharmaceuticals
Olorinab (APD371) is an oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2). Olorinab is an internally discovered investigational drug candidate that Arena is exploring for development in several indications, with an initial focus on visceral pain in gastrointestinal disorders. This compound, through its selectivity for CB2, versus the cannabinoid receptor 1 (CB1), was designed to provide pain relief while minimizing the risk of psychoactive adverse effects. The drug is currently in phase 2 of clinical trials for the treatment of irritable bowel syndrome.
Blautix: 4D Pharma
Blautix is a single strain Live Biotherapeutic product (LBP), being developed as a treatment for both IBS-C and IBS-D. Pre-clinical studies demonstrated its ability to address visceral hypersensitivity and other symptoms of IBS and increase microbiome diversity. A Phase I study in healthy volunteers and IBS patients showed that Blautix was well tolerated and an improvement in symptoms was also reported relative to placebo. The Phase II BHT-II-002 trial demonstrated an impact on overall response with regards to bowel habit and abdominal pain in IBS-C and IBS-D. Blautix was well tolerated, with a safety profile comparable to placebo.
Irritable bowel syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Irritable bowel syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Irritable bowel syndrome
There are approx. 24+ key companies which are developing the therapies for Irritable bowel syndrome. The companies which have their Irritable bowel syndrome drug candidates in the most advanced stage, i.e. phase II include Arena Pharmaceuticals.
Phases
This report covers around 24+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Irritable bowel syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Irritable bowel syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Irritable bowel syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Irritable bowel syndrome drugs.
Irritable bowel syndrome Report Insights
- Irritable bowel syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Irritable bowel syndrome Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Irritable bowel syndrome drugs?
- How many Irritable bowel syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Irritable bowel syndrome?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Irritable bowel syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Irritable bowel syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Arena Pharmaceuticals
- 4D Pharma
- OrphoMed
- Boston Pharmaceuticals
- RedHill Biopharma Limited
- Takeda
- Cosmo Technologies
- CinRx Pharma
- Rottapharm
- SK biopharmaceuticals
- Synthetic Biologics
- Biomica
- Dong-A ST Co Ltd
- Metacrine
- MGC Pharma
- Napo Pharmaceuticals
- Nobilis Therapeutics
- Novome Biotechnologies
- RQ-00310941
- Renexxion
- Sentia Medical Sciences
- Serentrix LLC
- Velicept Therapeutics
- Vitality Biopharma
- Oxford Cannabinoid Technologies
Key Products
- Olorinab
- Blautix
- ORP-101
- BOS-589
- BEKINDA
- Mesalamine
- Rifamycin controlled-release
- CIN 103
- Dexloxiglumide
- Relenopride
- Lovastatin modified release
- BMC426
- DA-6886
- MET409
- Crofelemer
- NBTX-001
- RQ-00310941
- Ser-224
- Velicept
- VBX-100
- AAT 730
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/mclin0
